Intl. Congress form | International Congress Report | International Congress Report For Faculty | The report of world leish6 (2017) by Dr. Ali Khamesipour

Home

Code : 9345-353599 Created Date : Wednesday, November 8, 2017 Visit : 2035

The report of world leish6 (2017) by Dr. Ali Khamesipour

Application Code :

762-0217-0047

Created Date : Tuesday, September 5, 2017-14:52 14:52:34Update Date : Wednesday, November 1, 2017-10:22 10:22:11
IP Address : 192.168.98.130Submit Date : Wednesday, November 1, 2017-10:23 10:23:12Email :ali.khamesipour@gmail.com

Personal Information

Name :	ali
Surname :	khamesipour
School/Research center :	Center for Research and Training in Skin Diseases and Leprosy
If you choose other, please name your Research center :
Position :	Professor
Tel :	+889-706-57

Information of Congress

Title of the Congress :	worldleish6 (2017)
Title of your Abstract :	Ki l l ed Vacci nes
Destination Country :	Spain
From :	Tuesday, May 16, 2017
To :	Saturday, May 20, 2017
Abstract(Please copy/paste the abstract send to the congress) :	Cutaneous leishmaniasis (CL) has been well known for centuries in Latin America and some parts of Asia. As an example AbuBakr Muhammad ibn Zakariya al-Razi (854 CE – 925 CE), has explained the vector born nature of CL lesion. Recovery of CL lesion accompanies with protection against further lesion development. Development of Leishmania vaccine was initiated by using several species of Leishmania. In Brazil, first 5strain of killed Leishmania braziliensis and mexicana complexes,and later a single strain of L.amazonensis and in Venezuela L. mexicana were tested for prophylaxis and therapy. In Ecuador first a trivalent vaccine and later along with Colombia a single strain of killed L.amazonensis was tested for prophylaxis. In old world single and multiple doses of killed L. major were tested in Iran against zoonotic and anthroponotic CL and in Sudan against visceral leishmaniasis. The results of phase 3 trials of different preparations of killed Leishmania vaccines alone or mixed with mainly BCG (as an adjuvant) which were tested in thousands of volunteers results showed that the vaccines are safe and induced immune responses (shown by in vitro and in vivo). The efficacy rate in different trials varies between -14 to 72%. Leishmanization (LZ) is an inoculation of L. major at a predetermined site of the body which usually produces a self-healing lesion and upon healing the individual is protected against further CL lesion development. Historically and still LZ is the most effective control measure against CL. In 1980s more than 2 million soldiers and civilians were leishmanized and showed to be highly effective. Challenges and reasons for killed vaccine failure are partly as follow; lack of an appropriate adjuvant, evaluation of killed vaccines in the field is not precise due to nature of the disease. The only way to evaluate Leishmania vaccines is to use live challenge. Global attentions need to solve the problems of live challe
Keywords of your Abstract :	cutaneous leishmaniasis/killed Vaccines /
Acceptance Letter :	http://gsia.tums.ac.ir/images/UserFiles/40259/Forms/762/3_1.pdf
The presentation :	Oral
The Cover of Abstract book :
Published abstract in the abstract book with the related code :	http://gsia.tums.ac.ir/images/UserFiles/40259/Forms/762/مقاله_002.pdf
Where has your abstract been indexed? :	ISI
If you choose other, please name :

The Congress Reporting Form

How many volunteers were present at the Congress? :	more than 2000
Delegates from which countries presented in the congress? :	Iran, Iraq, Afghanistan, India, Switzerland, Poland UK, USA, Brazil,France,Germany,India,Canada,sudan,sweden,scatland,Belgium,Africa,.....
Were the delegates of any other organizations present in the congress? :	Yes
If yes, please write the names of the organizations in the box :	WHO, DNDi, etc.
What were the responses to your talking points? Were specific questions or concerns raised? :	Yes, there was discussion and questions the main one was why leishmanization in Iran was stopped.
If you met staff members, please list their full names & positions. :	Prof. Marie-Paule Kieny, General Director of WHO, Dr Byron Arena, Jorje Alvar DNDi, Dr David Sacks from NIH, I have met 100 hundred people do you need all names
Please inform us if there are any follow up actions we need to talk with the members of the congress :	Yes I have been invited to give a lecture in leishmaniasis elimination in India
Your experiences about the travel processes(Providing ticket, accommodation,...) :	It is very difficult especially for visa I had to get visa from WHO
Please give a briefing of your own observations and outcomes of the congress: :	This congress is very important for leishmaniasis and you can meet all the experts

Home Printer Friendly Tell a Friend Comment

Your Comments :